Therini Bio, Inc.

Therini Bio is a clinical-stage biotech company founded in 2016, with a focus on developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. By selectively targeting toxic fibrin accumulation, the company aims to tackle neuroinflammation in debilitating diseases such as Alzheimer’s disease (AD) and Diabetic Macular Edema (DME). The foundational science behind Therini Bio's work originated from technology discovered in Katerina Akassoglou’s, Ph.D., laboratories at the Gladstone Institutes at the University of California San Francisco (UCSF) and formerly the University of California San Diego (UCSD). The company has attracted substantial funding, with a $36.00M Series A investment announced on 27 April 2023. Notably, the top-tier syndicate of life sciences investors includes Alzheimer's Drug Discovery Foundation, SV Health Investors’ Biotech Fund, Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures. This investment reflects confidence in the potential of Therini Bio's approach and technologies to address unmet medical needs in the Biotechnology and Health Care industries. In summary, Therini Bio's innovative approach to developing immunotherapies for neuroinflammation, its strong foundation in scientific research, and the substantial backing from prominent investors position it as a compelling player in the biotech landscape, with the potential to make a significant impact in addressing diseases driven by vascular dysfunction.